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A B S T R A C T
Background: Mortality and hospitalization due to asthma have decreased in many European countries, but
asthma symptoms still cause a lot of morbidity and costs.
Objectives: We evaluated prevalence trends of asthma, asthma symptoms and allergic rhinoconjunctivitis in
adults aged 20–69 years during a 20-year period from 1996 to 2016 in the city of Helsinki, the capital of Finland.
Methods: Three cross-sectional postal surveys were conducted in random population samples 10 years apart. In
1996, 2006 and 2016, a total of 6062 (response rate 75.9%), 2449 (61.9%) and 4026 subjects (50.3%) took part,
respectively.
Results: In all responders, the prevalence of physician-diagnosed asthma was 6.6% in 1996, 10% in 2006 and
10.9% in 2016. The prevalence increased from 1996 to 2006, but stabilized from 2006 to 2016, both in men and
women and in smokers and non-smokers. The prevalence of current asthma (8.5% in 2006 and 8.8% in 2016)
and of asthma with rhinoconjunctivitis (7.6% in 2006 and 7.5% in 2016) remained also at the same level.
Allergic rhinoconjunctivitis decreased significantly from 2006 (42.7%) to 2016 (39.0%, p= 0.004). Those with
physician diagnosed asthma reported significantly less symptoms in 2016 compared to 2006 and 1996, although
there was no change in smoking habits or medication use. Young asthmatics (20–29 years) without rhino-
conjunctivitis reported least symptoms.
Conclusion: Previously observed increase of physician-diagnosed asthma prevalence in adults seems to be le-
velling off in Helsinki, and patients have fewer symptoms than 20 years ago. In addition, allergic rhino-
conjunctivitis is less frequent than 10 years earlier. (247 words).
1. Introduction
Over the last decades, the prevalence of asthma has been increasing
worldwide, but improved management and understanding of the dis-
ease have reduced morbidity and mortality [1]. However, asthma re-
mains a major public health concern with high costs both to the patients
and society. The reasons for asthma increase after the Second World
War have been debated. Currently, there is growing evidence that re-
duced contact with natural environments and immune regulating mi-
crobes may play a role in the pathogenesis of allergic disease, including
asthma [2,3].
Asthma has different phenotypes, symptoms and severity [4–6].
Allergic rhinitis, smoking and obesity are recognised risk factors to
asthma and poor asthma control [7–9]. Symptoms vary from mild
coughing and sputum production to breathlessness caused by airway
obstruction, to severe exacerbations, and even to death. Effective pre-
ventive measures have not been established, but proactive management
of symptoms and prevention of exacerbations with guided self-man-
agement have considerably improved patients’ ability to live normal life
[10,11].
In Finland, specific programmes have been implemented to reduce
the burden of these conditions. The Asthma Programme (1994–2004)
changed the first line treatment from inhaled bronchodilators to corti-
costeroids and educated health care professionals and patients to stop
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exacerbations effectively. The Programme reduced the number of hos-
pital days due to asthma by 54% [11]. The recent Allergy Programme
(2008–2018) aimed to improve immunological tolerance, endorse al-
lergy health and cut down costs. The mid-term results indicate that
asthma burden continues to decrease in Finland [12].
We have followed asthma and rhinitis prevalence, symptoms and
medication in the city of Helsinki in 1996, 2006 and 2016. In the
present study, we report the results of the 2016 survey and give an
overview of the 20-year trends.
2. Population and methods
2.1. Study population
Three cross-sectional postal surveys were mailed in 1996, 2006 and
2016 to randomly selected adult population, aged 20–69 years, in the
city of Helsinki. The genders were randomized separately in 10 years
age cohorts taking into account the overall gender distribution in the
population. Each survey was conducted in early spring, before the
pollen season. In 1996, 6062 individuals responded, 2449 in 2006 and
4026 in 2016 (response rates 75.9%, 61.7% and 50.3%, respectively).
The population samples were obtained from the Finnish National
Population Registry.
The invited individuals were given the opportunity to respond by
mail in 1996 and 2006, and by mail or via internet in 2016. Reminders
were sent twice each study year.
In 2016, of the 8000 invited subjects 17 refused to participate, 7
mailed an empty questionnaire and one had died. Of the remaining
7975 subjects 4026 (50.3%) responded. Twenty-eight questionnaires
were excluded because they were not adequately fulfilled. Thus, the
sample consisted of 3998 responders.
The study was approved by the Coordinating Ethics Committee of
Helsinki and Uusimaa Hospital District (200/13/03/00/2015).
2.2. Questionnaire
The Finnish version of the FinEsS (FinlandEstoniaSweden) postal
survey has been published previously [13]. The questions focus on re-
spiratory symptoms, asthma and risk factors like smoking habits.
2.3. Questions and definitions
Self-reported allergic rhinoconjunctivitis. Do you have now or have you
previously had allergic rhinitis (e.g. hay fever) or allergic eye symp-
toms?
Physician-diagnosed asthma. Have you been diagnosed by a doctor as
having asthma?
Asthma with rhinoconjunctivitis. Positive answers to (1) physician-
diagnosed asthma, and (2) self-reported allergic rhinoconjunctivitis.
Asthma without rhinoconjunctivitis. A positive answer to (1) physi-
cian-diagnosed asthma, and (2) a negative answer to
rhinoconjunctivitis.
Current asthma. Physician diagnosed asthma in combination with a
positive answer to at least one of the following questions: (1) have you
had shortness of breath during the last 12 months, (2) have you had any
wheeze during the last 12 months, or (3) do you currently use asthma
medication?
Asthma medication use. Do you currently use asthma drugs (regularly
or as needed)?
Asthma symptoms. Do you have now, or have you had asthma
symptoms during the last 12 months (breathlessness with or without
cough or wheezing)?
Longstanding cough. Have you had longstanding cough during the
last 12 months?
Sputum production. Have you brought up phlegm on most days for at
least three months yearly during the last two years?
Wheeze. Is it usual that you have wheezing, whistling or noisy
sounds in your chest when breathing?
Past year wheeze. Have you had wheezing or whistling in your chest
at any time in the last 12 months?
Dyspnoea with wheeze. Have you been breathless when the wheezing
sound has been present?
Wheeze without cold. Have you had wheezing or whistling when you
did not have a cold?
Asthmatic wheeze. A positive answer to wheeze, breathless with
wheeze, and wheeze without cold during the last year.
Morning dyspnoea. Have you waked up with a feeling of tightness in
your chest at any time during the last year?
Smoker. Current smoker or having stopped smoking during the last
year.
Ex-smoker. Stopped smoking more than a year prior to the study.
Non-smoker. Neither current smoker nor ex-smoker.
2.4. Statistical analyses
All analyses were performed using IBM SPSS version 23.0.
Descriptive statistics i.e. frequencies and percentages were used to de-
scribe the study populations. Chi-square test was used to analyse dif-
ferences between groups. p < 0.05 was regarded as statistically sig-
nificant. Odds ratios (OR) for physician diagnosed asthma were
estimated with logistic regression model adjusted for year, age and sex.
3. Results
The characteristics of the study population each study year, divided
to men and women and in 10 years age cohorts are shown in Table 1.
The development of the asthma prevalence is given in Table 2 and
Fig. 1. The prevalence of physician diagnosed asthma, current asthma
and asthma with rhinoconjunctivitis increased significantly during the
first 10 years of the observation period but remained at the same level
during the latter period from 2006 to 2016. The prevalence of physician
diagnosed asthma was 6,6% in 1996, 10.0% in 2006, and 10.9% in
Table 1
Age, gender and smoking of the study population in the three FinEsS questionnaire surveys in 1996, 2006 and 2016 in the city of Helsinki.
Men 1996 Men 2006 Men 2016 Women 1996 Women 2006 Women 2016
N (%) 2598 (42.9%) 1084 (44.3%) 1693 (42.3%) 3460 (57.1%) 1365 (55.7%) 2305 (57.7%)
Mean (SD) age, years 42.3 (13.1) 45.0 (13,9) 45.5 (14.4) 42.2 (13.3) 45.4 (14.1) 45.2 (15.0)
Age 20–29 506 (19.5%) 200 (18.5%) 290 (17.1%) 758 (21.9%) 277 (20.3%) 457 (19.8%)
30-39 656 (25.3%) 224 (20.7%) 392 (23.2%) 831 (24.0%) 254 (18.6%) 481 (20.9%)
40-49 599 (23.1%) 236 (21.8%) 283 (16.7%) 787 (22.7%) 240 (17.6%) 373 (16.2%)
50-59 490 (18.9%) 219 (20.2%) 356 (21.0%) 647 (18.7%) 323 (23.7%) 469 (20.3%)
60-69 347 (13.4%) 205 (18.9%) 363 (21.4%) 437 (12.6%) 271 (19.9%) 509 (22.1%)
Smokers 1013 (39.0%) 357 (32.9%) 493 (29.1%) 1063 (30.7%) 330 (24.2%) 493 (21.4%)
Ex-smokers 570 (21.9%) 265 (24.4%) 414 (24.5%) 504 (14.6%) 284 (20.8%) 469 (20.3%)
Non-smokers 1013 (39.0%) 463 (42.7%) 808 (47.7%) 1897 (54.8%) 751 (55.0%) 1368 (59.3%)
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2016, of current asthma 5.8%, 8.5%, and 8.8%, and of asthma with
rhinoconjunctivitis 4.7%, 7.6% and 7.5%, respectively. Asthma without
rhinoconjunctivitis still increased slightly from 2006 to 2016, both in
men and women and in smokers and non-smokers.
Young men aged 20–29 years were exceptions as physician-diag-
nosed asthma increased among them from 2006 to 2016 (Table 3).
Alarmingly 40% of them reported smoking, when the figure was 18,8%
ten years earlier. Asthma prevalence increase is seen also among 40–49
-years, but the increase is not significant among men or women sepa-
rately. In women, the prevalence of physician diagnosed asthma was
stable from 2006 to 2016 both among non-smokers (9.7% vs 9.1%) and
smokers (12.4% vs 12.8%).
In 20 years, a remarkable decrease was observed in asthma symp-
toms in those subjects with physician-diagnosed disease regardless
whether they were smoking or not (Fig. 2). In 1996, 62.6% of the non-
smoking asthmatics reported wheezing during the past year, while the
figure was 45.3% in 2016 (p=0.002). In smokers the respective figures
were 80.2% and 66.9% (p=0.040). Young asthmatic subjects, aged
20–29 years and without rhinoconjunctivitis reported the lowest oc-
currence of asthma symptoms. For example, not more than 8.3% of
them reported asthmatic wheeze (compared to 25.2% in all asthmatics).
The asthmatics also reported somewhat less rhinoconjunctivitis in 2006
compared with 2016 (75.9% vs 68.6%, p= 0.044).
Altogether, the prevalence of self-reported allergic rhinoconjuncti-
vitis decreased significantly from 2006 to 2016 (42.7% vs 39.0%,
p=0.004) (Table 2). This was observed among non-smokers (42.8% vs
39.2%, p=0.039) and in women (45.9% vs 41.3%, p=0.006). The
prevalence decreased also among men, but not significantly (38.7% vs
36.0%, p= 0.16).
Among all responders, smoking decreased and the use of asthma
medication increased in 20 years (Tables 1 and 2). In asthmatics,
Table 2
All responders. Prevalence of asthma and asthma related symptoms from 1996 to 2016. Current asthma=physician-diagnosed asthma AND wheeze OR dyspnoea OR
use of asthma medication during the last 12 months. Asthmatic wheeze=wheeze during the last 12 months AND dyspnea with wheeze AND wheeze without cold.
Symptom 1996 2006 2016 p-value 1996 vs 2016 p-value 2006 vs 2016
Physician-dg asthma 398 (6.6%) 245 (10.0%) 437 (10.9%) 0.000 0.240
Current asthma 352 (5.8%) 208 (8.5%) 351 (8.8%) 0.000 0.692
Asthma with rhinoconjunctivitis 286 (4.7%) 186 (7.6%) 300 (7.5%) 0.000 0.893
Asthma without rhinoconjunctivitis 112 (1.8%) 59 (2.4%) 137 (3.4%) 0.000 0.021
Asthma medication 363 (6.0%) 229 (9.4%) 464 (11.6%) 0.000 0.005
Asthma symptoms 784 (12.9%) 371 (15.1%) 574 (14.4%) 0.014 0.383
Prolonged cough 1207 (19.9%) 463 (18.9%) 720 (18.0%) 0.055 0.377
Sputum production 734 (12.1%) 271 (11.1%) 328 (8.2%) 0.000 0.000
Wheeze 440 (7.3%) 177 (7.2%) 279 (7.0%) 0.856 0.705
Past year wheeze 1210 (20.0%) 542 (22.1%) 756 (18.9%) 0.007 0.002
Dyspnoea with wheeze 627 (10.3%) 268 (10.9%) 313 (7.8%) 0.000 0.000
Wheeze without cold 788 (13.0%) 339 (13.8%) 423 (10.6%) 0.000 0.000
Morning dyspnoea 1512 (25.0%) 592 (24.2%) 854 (21.4%) 0.000 0.009
Asthmatic wheeze 444 (7.3%) 189 (7.7%) 213 (5.3%) 0.000 0.000
Rhinoconjunctivitis 2234 (36.9%) 1045 (42.7%) 1561 (39.0%) 0.000 0.000
Fig. 1. Prevalence (%) of physician-diagnosed
asthma and asthma with and without rhino-
conjunctivitis by gender from 1996 to 2016.
Statistical comparison between 1996 and 2006 and
between 2006 and 2016 (*p < 0.05, **p < 0.01,
***p < 0.001, ns = non significant). For all sub-
jects, asthma prevalence, with or without rhino-
conjunctivitis, did not increase between 2006 and
2016. RC = rhinoconjunctivitis.
Table 3
All responders. The prevalence of physician diagnosed asthma, and in men and
women by age group from 1996 to 2016.
ALL 1996 2006 2016 P-VALUE P-VALUE
AGE GROUP 1996 vs 2016 2006 vs 2016
20–29 80 (6.3%) 46 (9.6%) 104 (13.9%) 0.000 0.026
30–39 81 (5.4%) 54 (11.3%) 88 (10.1%) 0.000 0.486
40–49 81 (5.8%) 37 (7.8%) 76 (11.6%) 0.000 0.035
50–59 66 (5.8%) 60 (11.1%) 87 (10.5%) 0.000 0.759
60–69 90 (11.5%) 48 (10.1%) 82 (9.1%) 0.286 0.570
MEN
20–29 31 (6.1%) 16 (8.0%) 50 (17.2%) 0.000 0.003
30–39 23 (3.5%) 20 (8.9%) 51 (13.0%) 0.000 0.127
40–49 34 (5.7%) 18 (7.6%) 32 (11.3%) 0.012 0.157
50–59 20 (4.1%) 23 (10.5%) 34 (9.6%) 0.001 0.711
60–69 37 (10.7%) 23 (11.2%) 25 (6.7%) 0.099 0.061
WOMEN
20–29 49 (6.5%) 30 (10.8%) 54 (11.8%) 0.003 0.684
30–39 58 (7.0%) 34 (13.4%) 37 (7.7%) 0.004 0.013
40–49 47 (6.0%) 19 (7.9%) 44 (11.8%) 0.003 0.123
50–59 46 (7.1%) 37 (11.5%) 53 (11.3%) 0.023 0.946
60–69 53 (12.1%) 25 (9.2%) 57 (10.9%) 0.483 0.473
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however, asthma medication use from 1996 to 2016 (71.1% vs 70.3%),
smoking (33.2% vs 30.6%), and body mass index (BMI, 26.0 vs 26.0)
remained the same.
Results of the regression analysis are given in Table 4. The increase
of physician diagnosed asthma was evident from 1996 to 2006, but
became slower during the last 10 years. Although the overall asthma
increase seemed to level off from 2006 to 2016, it was still observed in
some subgroups like the youngest (20–29) and the middle-aged (40–49
years) responders.
4. Discussion
The increase of prevalence of physician diagnosed asthma seems to
be levelling off in the city of Helsinki. The prevalence of current asthma
and asthma with rhinoconjunctivitis increased from 1996 to 2006 but
have been stable during the last decade. Asthma symptoms among
those with physician diagnosed asthma and the prevalence of rhino-
conjunctivitis have decreased significantly. Those subjects with physi-
cian diagnosed asthma without rhinoconjunctivitis reported the least
symptoms.
The Finnish Asthma Programme 1994–2004 focused on early in-
tervention with anti-inflammatory medication and disease control.
Health-care personnel was trained to find the patients at early stage of
disease and treat them effectively. Asthmatics were educated to stop
exacerbations proactively by guided self-management. Tobacco legis-
lation was tightened to eradicate smoking in work places and later in-
doors in public buildings [11]. Public awareness of asthma and allergies
was increased by special campaigns. The Programme reduced sig-
nificantly the asthma burden, e.g. in terms of hospital days [11,14] and
costs [15]. In long-term, the decrease of annual costs per patient has
been remarkable, even 72% from 1987 to 2013.
Asthma prevalence has increased over the past decades [16–21].
However, it has been discussed if the rise seen in asthma and asthma
symptom prevalence would be a consequence of increased disease
awareness and better diagnostics [22]. Some studies have also sug-
gested a plateau in prevalence trends [23,24]. In the previous 2006
survey in Helsinki, the prevalence was still rising [25] but has been
stable since then. The worldwide prevalence is affected by multiple
factors like fast urbanization changing environment and lifestyle [1–3]
and economic development [19,26]. Smoking and exposure to tobacco
smoke have decreased in several countries in recent years, and may
partly explain the decreasing prevalence [27–31]. In the present study,
respiratory symptoms decreased both in all responders and in asth-
matics. Exposure to tobacco smoke has decreased in Finland, and the
Tobacco Act aims to end the use of tobacco products by the year 2030.
Dietary habits are known to affect several diseases such as cardio-
vascular disease, type 2 diabetes and cancer [32]. Some studies suggest
that fruit and vegetable consumption would decrease asthma risk and
improve disease control, but the evidence is still modest [33–35].
Processed meat may have a negative effect on asthma control [36]. In a
recent French study, Mediterranean like diet was associated with better
asthma control even after adjustments for smoking, educational level,
and physical activity [37]. Even though we have no data on dietary
habits in our study, a recent report from Finland found that the intake
of vegetables and fruits was closer to dietary guidelines in women than
in men. Younger men consumed less vegetables, fruits and berries than
older men [38]. It is possible that the differences in dietary habits could
have contributed to the higher asthma risk in young men in the present
study.
In all responders, respiratory and asthma symptoms decreased in
our study, while they were stable in Norrbotten County, Sweden [16].
In Norrbotten, 18.6% reported wheezing during the last 12 months in
2006 and 18.1% in 2016. In Helsinki, 22.1% of responders reported
wheezing during the past year in 2006 and 18.9% in 2016 (p=0.002).
The prevalence of asthmatic wheeze decreased also significantly in
Helsinki (7.7% in 2006 vs 5.3% in 2016) but was stable in Sweden
(7.4% in 2006 vs 7.2% in 2016) [16]. The asthma prevalence increased
Fig. 2. Prevalence (%) of respiratory symptoms among responders who reported a physician-diagnosed asthma from 1996 to 2016. Statistical comparison between
1996 and 2016 (*p < 0.05, **p < 0.01, ***p < 0.001).
Table 4
All responders. Adjusted Odds ratios (OR) for physician diagnosed asthma in
2006 and 2016, compared with 1996 and 2006 as a reference by age group and
gender. Logistic regression with physician-diagnosed asthma as outcome and
year of study, age (continuous) and sex as covariates. In separate models for
males and females the models are not adjusted for sex. Bold figures indicate














20-29 1.586 1.086–2.318 2.365 1.738–3.220 1.525 1.054–2.206
30-39 2.379 1.649–3.433 1.972 1.440–2.702 0.862 0.601–1.236
40-49 1.383 0.922–2.074 2.091 1.506–2.903 1.529 1.011–2.313
50-59 1.929 1.330–2.798 1.890 1.352–2.642 0.964 0.679–1.368
60-69 0.857 0.591–1.242 0.753 0.547–1.038 0.873 0.598–1.275
All 1.550 1.310–1.833 1.742 1.510–2.010 1.104 0.936–1.302
Men 1.669 1.278–2.179 2.213 1.765–2.775 1.266 0.981–1.633
Women 1.480 1.193–1.837 1.479 1.229–1.780 1.001 0.805–1.243
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among young men in our study, and the same worrying trend is seen
also in Sweden [39]. In a Norwegian study overweight increased the
odds of asthma in adolescents [8]. In our study, BMI was the same in
2006 and in 2016 among 20–29 years old men so obesity does not
explain the increase in asthma prevalence. In the present study, the
response rate was lowest among young men and possible report bias
may partly explain the increase in prevalence found in men aged 20–29
years.
In asthmatics, the decrease in symptoms was observed both in our
study and in Norrbotten county in 1996–2016 [16]. The smoking habits
of responders with physician diagnosed asthma have remained the
same in Helsinki, but active smoking has halved among Swedish asth-
matics in 20 years (24.7% in 1996 vs 11.1% in 2016). This may partly
explain the symptom reduction in Sweden [40]. In the asthma barom-
eter survey carried out in Finnish pharmacies in 2001 and 2010, the
self-reported asthma severity has decreased in 10 years in line with the
present study results [41]. Air pollution has not been a problem in
Finland and it is unlikely that it would explain the decrease in asthma
symptoms. According to reports from Helsinki Region Environmental
Services Authority the air quality is good and has not changed for
decades. It is likelypossible that the decrease in asthma symptoms in
our study, and Finland in general, is at least in part due to active
symptom control measures taken during the Finnish Asthma and Al-
lergy programmes [11,12].
Asthma medication has improved since 1996. Fluticasone-salme-
terol -combination was launched in Finland in 1996 and budesonide-
formoterol in 2001. These medications were already used in 2006 [42].
Overall asthma medication use has been the same during 20 years in
our study, but the use of combination products increased by 20% in
2008–2015, according to The Social Insurance Institution of Finland.
The symptom reduction is significant both from 1996 to 2006 and from
2006 to 2016. Therefore, it is unlikely that combination products alone
would be an essential explanation for the better control.
Self-reported rhinoconjunctivitis has slightly decreased during the
last 10 years in our study, but the prevalence is still high, 39,0%. In a
Swedish study the prevalence of self-reported rhinoconjunctivitis is
somewhat lower but has been rising, from 24.8% in 2006 to 27.8% in
2016 [16]. This fits to another survey from Sweden, where sensitization
to common allergens was on rise in schoolchildren [43].
4.1. Strengths and limitations
The present study has several strengths. A large sample size, with a
wide age span, reflects general population. The study samples were
randomized in 10 years age cohorts taking into account the overall
gender and age distribution in the population. The study questions were
same in 1996, 2006 and 2016. We present results from three surveys,
each 10 years apart from the same area. The three surveys were done
with similar methods, so the results would be comparable. Asthma di-
agnose is always based on objective lung function measurements in
Finland due to the drug reimbursement system making asthma diag-
noses reliable. Similar postal questionnaire study is done also in Sweden
in 1996, 2006 and 2016. We are working on a joint study project with
Swedish Finess group comparing our results in 1996–2016.
The number of invited subjects in 2006 study was half of that in-
vited in 1996 and 2016, study then performed by Filha [25]. The pre-
sent results show similar amount of physician diagnosed asthma and
asthma with rhinoconjunctivitis in 2006 and in 2016. Also the 95%
confidence intervals for prevalence estimates of physician diagnosed
asthma and asthma with and without rhinoconjunctivitis overlapped in
the 2006 and 2016 cohorts indicating that the difference in cohort size
was most probably not relevant.
The response rate declined over the years from 75.9% in 1996 to
61.7% in 2006, and to 50.3% in 2016. Participation rates have de-
creased by time in epidemiological studies as a general trend. The re-
sponse rate has been about the same in other epidemiological studies as
in our study, for example 55% in Copenhagen City Heart Study and
53% in a Swedish follow up study on prevalence of asthma [16,44]. The
response rate is still moderate considering general decline in response
rates during last decades [16,43]. In the present study, a telephone
interview of a sample of non-responders was planned but denied by the
ethics committee. Therefore, we performed a non-responder-analysis
based on information that was available for responders and non-re-
sponders. We found that Finnish or Swedish speaking subjects re-
sponded more actively compared to those with other native languages.
The youngest subjects responded less actively compared to the oldest
subjects. To adjust for differences in response rates, we performed
analyses for asthma prevalence and smoking habits among respondents
to the first, second and third mailing of the questionnaire separately. No
significant differences were found in asthma prevalence. Respondents
to the first and second mailing were less likely to be smokers than re-
spondents to the third mailing (22.7%, 23.9%, and 30.2%,
p=0.013%). Earlier, studies have found non-responders being more
often young, male and smokers [45,46]. This is in line with our find-
ings. None of the non-responder studies concluded that non-response
bias would affect the prevalence of asthma [45,46]. However, in a
previous Finnish non-responder-study [47] symptomatic individuals
were more likely to respond than individuals without symptoms.
Threrefore, some non-responder cannot be excluded in the present
study in the youngest age groups.
Study limitations also included that no objective measurement of
lung function was performed. In Finland, asthma is confirmed with lung
function testing, which is a prerequisite for a special reimbursement for
asthma medication costs. Therefore, physician diagnosed asthma is an
accurate measure to follow asthma trends in Finland.
5. Conclusions
The increase of prevalence of asthma seems to be levelling off in
Helsinki. In general, asthmatics had fewer symptoms in 2016 than
2006. At the same time, prevalence of self-reported rhinoconjunctivitis
has decreased significantly. Changes in prevalence are small but sig-
nificant in a large population. The effectively implemented national
Asthma Programme (1994–2004) and Allergy Programme (2008–2018)
changed management and increased public awareness. They may have
reduced symptoms and their severity. Our results encourage systematic
work to diagnose and treat asthma and respiratory symptoms effec-
tively for better public health.
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